Compliance Rate

Compliance Rate 50.0%
Compliant submissions 1
Incompliant submissions 1
Total trials 2

My Organizations' Clinical Trials

Showing 3050 of 3499 entries
View as:

Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma

Phase: N/A Priority: Normal
NCT ID: NCT04941274 Org: User:
Start: 09/29/21 End: 06/01/28 Due: 06/01/29

Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT05886036 Org: User:
Start: 01/23/24 End: 10/31/26 Due: 10/31/27

Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery

Phase: N/A Priority: Normal
NCT ID: NCT00770809 Org: User:
Start: 12/01/08 End: 07/10/25 Due: 07/10/26

Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00433511 Org: User:
Start: 11/02/07 End: 02/22/26 Due: 02/22/27

Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT03289910 Org: User:
Start: 09/24/18 End: 12/19/25 Due: 12/19/26

SS1(dsFV)PE38 Plus Pemetrexed and Cisplatin to Treat Malignant Pleural Mesothelioma

Phase: N/A Priority: Normal
NCT ID: NCT01445392 Org: User:
Start: 11/14/07 End: 10/03/16 Due: 10/03/17

Natural History of KSHV-Associated Multicentric Castleman s Disease

Phase: N/A Priority: Normal
NCT ID: NCT04968288 Org: User:
Start: 11/17/21 End: 01/01/35 Due: 01/01/36

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

Phase: N/A Priority: Normal
NCT ID: NCT05389423 Org: User:
Start: 06/27/23 End: 06/01/32 Due: 06/01/33

Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

Phase: N/A Priority: Normal
NCT ID: NCT00334815 Org: User:
Start: 06/15/06 End: 02/22/26 Due: 02/22/27

Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT01169337 Org: User:
Start: 01/24/11 End: 03/19/26 Due: 03/19/27

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

Phase: N/A Priority: Normal
NCT ID: NCT05256225 Org: User:
Start: 11/16/22 End: 10/31/27 Due: 10/31/28

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Phase: N/A Priority: Normal
NCT ID: NCT05564390 Org: User:
Start: 06/18/24 End: 05/15/29 Due: 05/15/30

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

Phase: N/A Priority: Normal
NCT ID: NCT02194738 Org: User:
Start: 09/26/14 End: 09/28/26 Due: 09/28/27

Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01038778 Org: User:
Start: 10/29/09 End: 02/12/26 Due: 02/12/27

Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00006363 Org: User:
Start: 11/30/00 End: - Due: -

Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT01522976 Org: User:
Start: 03/01/12 End: 03/19/26 Due: 03/19/27

Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma

Phase: N/A Priority: Normal
NCT ID: NCT02659930 Org: User:
Start: 01/13/16 End: 01/01/28 Due: 01/01/29

Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT02166463 Org: User:
Start: 03/19/15 End: 10/03/25 Due: 10/03/26

Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT03983824 Org: User:
Start: 05/05/20 End: 06/30/26 Due: 06/30/27

Assessment of Bone Mineral Density in People Living With HIV and KSHV Associated Malignancies: A Retrospective Longitudinal Analysis

Phase: N/A Priority: Normal
NCT ID: NCT04742387 Org: User:
Start: 02/04/21 End: 12/31/25 Due: 12/31/26

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01272037 Org: User:
Start: 01/15/11 End: 10/01/32 Due: 10/01/33

Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04052555 Org: User:
Start: 09/24/20 End: 11/20/25 Due: 11/20/26

Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)

Phase: N/A Priority: Normal
NCT ID: NCT02595944 Org: User:
Start: 07/22/16 End: 12/31/25 Due: 12/31/26

Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S02)

Phase: N/A Priority: Normal
NCT ID: NCT06611553 Org: User:
Start: 09/13/24 End: 10/14/25 Due: 10/14/26

Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)

Phase: N/A Priority: Normal
NCT ID: NCT01419561 Org: User:
Start: 09/08/11 End: 12/31/28 Due: 12/31/29